Oppenheimer Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.59M | Sell |
8,391
-980
| -10% | -$171K | 0.02% | 609 |
|
|
2025
Q4 | $1.59M | Sell |
9,371
-365
| -4% | -$56K | 0.02% | 562 |
|
|
2025
Q3 | $1.28M | Sell |
9,736
-646
| -6% | -$77.5K | 0.01% | 696 |
|
|
2025
Q2 | $1.1M | Buy |
10,382
+191
| +2% | +$20.7K | 0.01% | 725 |
|
|
2025
Q1 | $1.27M | Buy |
10,191
+603
| +6% | +$78.7K | 0.02% | 658 |
|
|
2024
Q4 | $1.18M | Buy |
9,588
+1,867
| +24% | +$220K | 0.01% | 680 |
|
|
2024
Q3 | $860K | Sell |
7,721
-125
| -2% | -$13.7K | 0.01% | 752 |
|
|
2024
Q2 | $837K | Buy |
7,846
+1,272
| +19% | +$140K | 0.01% | 745 |
|
|
2024
Q1 | $792K | Sell |
6,574
-820
| -11% | -$100K | 0.01% | 738 |
|
|
2023
Q4 | $909K | Sell |
7,394
-592
| -7% | -$73.9K | 0.01% | 733 |
|
|
2023
Q3 | $1.03M | Sell |
7,986
-49
| -0.6% | -$6.53K | 0.02% | 683 |
|
|
2023
Q2 | $996K | Buy |
8,035
+185
| +2% | +$24.9K | 0.01% | 703 |
|
|
2023
Q1 | $1.15M | Buy |
7,850
+1,191
| +18% | +$176K | 0.02% | 648 |
|
|
2022
Q4 | $1.06M | Buy |
6,659
+42
| +0.6% | +$6.16K | 0.02% | 668 |
|
|
2022
Q3 | $882K | Sell |
6,617
-1,120
| -14% | -$170K | 0.02% | 687 |
|
|
2022
Q2 | $1.21M | Sell |
7,737
-80
| -1% | -$12.3K | 0.02% | 621 |
|
|
2022
Q1 | $1.22M | Buy |
7,817
+557
| +8% | +$80.8K | 0.02% | 685 |
|
|
2021
Q4 | $925K | Buy |
7,260
+1,514
| +26% | +$199K | 0.01% | 797 |
|
|
2021
Q3 | $748K | Buy |
5,746
+81
| +1% | +$12.2K | 0.01% | 826 |
|
|
2021
Q2 | $1.01M | Buy |
5,665
+65
| +1% | +$11.3K | 0.01% | 752 |
|
|
2021
Q1 | $920K | Buy |
5,600
+117
| +2% | +$19.3K | 0.01% | 755 |
|
|
2020
Q4 | $905K | Buy |
5,483
+244
| +5% | +$36.3K | 0.02% | 712 |
|
|
2020
Q3 | $747K | Buy |
5,239
+790
| +18% | +$97.9K | 0.01% | 698 |
|
|
2020
Q2 | $491K | Sell |
4,449
-9,152
| -67% | -$1.01M | 0.01% | 797 |
|
|
2020
Q1 | $1.36M | Buy |
13,601
+303
| +2% | +$39.2K | 0.03% | 447 |
|
|
2019
Q4 | $1.99M | Buy |
13,298
+494
| +4% | +$67.2K | 0.04% | 418 |
|
|
2019
Q3 | $1.64M | Buy |
12,804
+601
| +5% | +$80.6K | 0.04% | 452 |
|
|
2019
Q2 | $1.74M | Buy |
12,203
+161
| +1% | +$21.6K | 0.04% | 446 |
|
|
2019
Q1 | $1.72M | Sell |
12,042
-837
| -6% | -$109K | 0.04% | 444 |
|
|
2018
Q4 | $1.6M | Buy |
12,879
+1,598
| +14% | +$237K | 0.04% | 418 |
|
|
2018
Q3 | $1.9M | Sell |
11,281
-99
| -0.9% | -$17K | 0.04% | 433 |
|
|
2018
Q2 | $1.96M | Buy |
+11,380
| New | +$1.86M | 0.05% | 402 |
|
|
2017
Q3 | – | Sell |
-4
| Closed | -$1K | – | 1697 |
|
|
2017
Q2 | $1K | Sell |
4
-16
| -80% | -$2.45K | ﹤0.01% | 1636 |
|
|
2017
Q1 | $3K | Buy |
+20
| New | +$2.6K | ﹤0.01% | 1619 |
|
Other funds holding JAZZ
VPM
VCM
EC
Oppenheimer Asset Management's JAZZ Position: Q1 2026 in Review
Oppenheimer Asset Management reduced its Jazz Pharmaceuticals (JAZZ) stake by 10% in Q1 2026, selling an estimated $171K and leaving 8,391 shares worth $1.59M. The position accounts for 0.02% of the portfolio, ranked #609.
Oppenheimer Asset Management first reported a position in JAZZ in Q1 2017 and has held it in 34 quarters since. The position peaked at $1.99M in Q4 2019. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- Oppenheimer Asset Management held 8,391 shares of Jazz Pharmaceuticals worth $1.59M as of Q1 2026.
- Oppenheimer Asset Management sold 980 Jazz Pharmaceuticals shares in Q1 2026, an estimated $171K.
- Jazz Pharmaceuticals made up 0.02% of Oppenheimer Asset Management's portfolio in Q1 2026, its #609 holding.
- Oppenheimer Asset Management first reported a position in Jazz Pharmaceuticals in Q1 2017 and has held it in 34 quarters since.
- Oppenheimer Asset Management's Jazz Pharmaceuticals position peaked at $1.99M in Q4 2019.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on Oppenheimer Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.